Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02312960 · ClinicalTrials.gov registry record · Phase 4
Radium-223 Dichloride Long-term Follow-up Program
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 255
- Enrollment target
NCT02312960: Completed Phase 4 study, sponsored by Bayer.
NCT02312960 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 255 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02312960, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 255 participants
- Enrollment target
Study Summary
Patients will be followed up in this study after prior treatment with BAY88-8223 / Radium-223 dichloride / Xofigo.
Primary Outcome
Adverse events considered related to radium-223 dichloride or placebo (received in the feeder studies), first arising or worsening on or after the date the participant signed the 16996 informed consent.
Interventions
- OTHER Data Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2014-12-18 |
| Est. Completion | 2024-01-31 |
| Phase | Phase 4 |
What the finished NCT02312960 record still lists
NCT02312960 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 1 intervention - of which Data Collection is the first listed.
NCT02312960 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02312960 about?
NCT02312960 is a clinical study titled "Radium-223 Dichloride Long-term Follow-up Program". Patients will be followed up in this study after prior treatment with BAY88-8223 / Radium-223 dichloride / Xofigo.
What is the current status of trial NCT02312960?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 255 participants. The study started on 2014-12-18. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT02312960?
The interventions under investigation include: Data Collection (OTHER).
Who is sponsoring clinical trial NCT02312960?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02312960's enrollment target sits among peer trials
255 334th of 2000 higher than 1,664 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI